Stayble Therapeutics engages Ferghana Partners to support partnering activities

October 2023

Stayble Therapeutics AB (“Stayble” or the “Company”) today announces that it has entered into an agreement with the transaction advisor Ferghana Partners (“Ferghana”) ahead of the upcoming clinical results from the STA363 phase 2b study in patients with chronic back pain caused by degenerative disc disease. Provided results are positive, Ferghana will assist Stayble with international partnering activities for STA363, accelerate such activities, and supplement Stayble’s current resources.

In parallel with the progress of the STA363 phase 2b study, interest from potential partners has been growing, with several partners awaiting the top-line results. In the study, all patients have recently completed their follow-ups, and top-line data are expected to be presented in November or early December 2023.


Andreas Gerward, CEO of Stayble Therapeutics, comments:

“We are enthusiastic about the upcoming results from the STA363 study and the collaboration with Ferghana, a well-regarded specialist advisor with the right network to support us in partnering activities following potentially positive results. Their experience, expertise, and network will increase the possibilities of identifying partners with a good fit with STA363 and Stayble, thereby increasing shareholder value.”


Rawle Michelson, Managing Director of Ferghana Partners, comments:

“We are delighted to be working with Stayble Therapeutics in anticipation of the release of the results from the Phase 2b clinical trial in degenerative disc disease later this year. The drug candidate STA363 has the potential to be a game-changing treatment for patients with lower back pain where there is currently little treatment between analgesics and physiotherapy, and more invasive procedures like back surgery.”


About Ferghana Partners:

Ferghana Partners is a leading investment banking firm in the Life Sciences sector; specializing in the healthcare and specialty chemicals sectors. 




For more information

Andreas Gerward, CEO of Stayble Therapeutics AB


Phone: +46 730 808 397


About Stayble Therapeutics AB

Stayble is a clinical-stage pharmaceutical company developing the STA363 injection treatment for degenerative disc disease (DDD) and chronic disc herniation (LDH). Stayble’s vision is to offer patients a simple and effective treatment that addresses the underlying cause of the patient’s chronic pain and provides lasting pain relief and increased physical function. Aimed at patients not helped by physiotherapy and painkillers, the treatment is a single injection expected to last a lifetime and requires minimal rehabilitation. The company is now focused on clinical development and is conducting a Phase 2b clinical trial in DDD and a Phase 1b trial in LDH.


Svensk Kapitalmarknadsgranskning AB is the Company’s Certified Adviser.